AI's Impact on Hospital Billing: A Blue Cross Blue Shield Report

Blue Cross Blue Shield has released a report exploring artificial intelligence's (AI) influence on hospital billing practices. Utilizing data from Blue Health Intelligence® to analyze claims, particularly focusing on maternity admissions, the report highlights the frequent recording of acute blood loss anemia (ABLA) in cesarean deliveries as a secondary diagnosis.

The study identifies a rise in coding for acute posthemorrhagic anemia, indicative of significant blood loss that requires further treatment. Cases where ABLA was recorded without administered blood transfusions suggest potential misalignment in care levels and hint at AI-driven upcoding of complex conditions.

Critics argue that the report misunderstands Medicare Severity Diagnosis Related Group (MS-DRG) reimbursement methodologies and the Uniform Hospital Discharge Data Set (UHDDS) requirements. They highlight that adding secondary diagnoses increases hospital bills only if the condition's impact on patient care justifies a higher level of care.

In healthcare billing, payers wield significant power, with contracts often mandating that providers adapt to policy changes to remain network-status compliant. Aetna's Medicare Advantage plans, with severity-based payment policies, exemplify payor influence in cost negotiations.

The MS-DRG system considers approximately 25% of ICD-10-CM codes as complications or comorbidities (CCs or MCCs), affecting reimbursement based on factors like patient age and discharge status. Acute blood loss anemia qualifies as a CC, but its classification nuances require that CDI teams ensure clinical evidence supports coding, especially in maternal cases with variable physician practices.

Reported overuse of ABLA coding is concerning, yet data highlight its seriousness, especially given obstetric hemorrhage's rank as a major cause of severe maternal issues. Innovative procedures for managing hemorrhage risk, including uterotonic agents and fluid resuscitation during immediate care, also justify ABLA's inclusion as a secondary diagnosis.

Disputes regarding AI's role in upcoding reflect larger concerns about tightening payer criteria amidst rising healthcare costs. As hospitals navigate complex reimbursement landscapes, adhering to MS-DRG regulations while negotiating dynamic payer relationships becomes crucial for maintaining operational viability and revenue integrity.